The intraoperative use of recombinant activated factor VII in arterial switch operations

• DOI: 10.1017/s1047951120004072
• Publication Date: 2020-11-19T07:38:37Z
• Authors: Jessica Zink; Zachary A. Spigel; Christopher Ibarra; Erin A. Gottlieb; Iki Adachi; Carlos M. Mery; Michiaki Imamura; Jeffrey S. Heinle; Emmett Dean McKenzie; Charles D. Fraser; Ziyad M. Binsalamah
• Keywords: Recombinant Factor VIIa; Factor VII

Abstract Background: The rate of bleeding complications following arterial switch operation is too low to independently justify a prospective randomised study for benefit from recombinant factor VIIa. We aimed evaluate VIIa in pilot study. Methods: performed retrospective cohort patients undergoing 2012 2017. Nearest-neighbour propensity score matching on age, gender, weight, and associated cardiac defects was used match 27 controls not receiving 30 Fisher’s exact test compare categorical variables. Wilcoxon’s rank-sum continuous variables between cohorts. Results: Post-operative thrombotic were with administration (Odds Ratio (OR) 0.28, 95% CI 0.005–3.77, p = 0.336), nor any re-explorations bleeding. No intraoperative transfusion volumes different the controls. prothrombin time (10.8 [10.3–12.3] versus 15.9 [15.1–17.2], < 0.001) international normalised ratio (0.8 [0.73–0.90] 1.3 [1.2–1.4], 0.001]) lower relative Conclusions: In spite higher post-bypass packed red blood cell requirement, had similar incidence post-operatively. With no difference complications, improved post-operative laboratory haemostasis, warranted